Last reviewed · How we verify
ART-123
At a glance
| Generic name | ART-123 |
|---|---|
| Also known as | human recombinant thrombomodulin, thrombomodulin alfa, Recomodulin™ |
| Sponsor | Asahi Kasei Pharma America Corporation |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients (PHASE1)
- Exploratory Study of ART-123 for the Prevention of Cancer Treatment Related Symptoms in Patients With Postoperative Stage II / III Colon Cancer (PHASE2)
- A Trial Measuring ART-123 Ability to Prevent Sensory Neuropathy in Unresectable mCRC Subjects w/Oxaliplatin-based Chemo (PHASE2)
- Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy (PHASE3)
- The Safety And Efficacy of ART-123 in Subjects With Sepsis and Coagulopathy (PHASE3)
- Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis (PHASE3)
- Clinical Pharmacokinetics Study of ART-123 in Disseminated Intravascular Coagulation (DIC) Subjects With Renal Impairment (PHASE4)
- Safety and Efficacy of ART-123 in Subjects With Sepsis and Disseminated Intravascular Coagulation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ART-123 CI brief — competitive landscape report
- ART-123 updates RSS · CI watch RSS
- Asahi Kasei Pharma America Corporation portfolio CI